SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Home ▸ Investors ▸ Corporate Governance ▸ Our Leadership
Jonathan has over 30 years of experience in the global life sciences and biopharmaceuticals industry. At Syngene, he is responsible for strategy, strategy execution, leading the executive team and the Company’s business operations and steering its investment decisions.
Prior to joining Syngene, he held leadership positions at AstraZeneca for over a decade, including President and Director of AstraZeneca, Austria, and President, AstraZeneca, India. He has been a member of the Board of Directors of Syngene since 2016, Managing Director since 2020 and is a member of the Stakeholders Relationship & ESG Committee, the Risk Management Committee and the Science & Technology Committee.
He completed his BA in Business Studies & Economics from the University of Sheffield and holds an MBA from Durham University, United Kingdom.
Deepak oversees the finance, supply chain, legal, secretarial and plays an important role in driving strategy, improving profitability, identifying new opportunities, improving cash generation and enabling organizational growth.
Deepak was previously with Ather Energy, where he led the company to significant revenue growth over four years as the Chief Financial Officer. Prior to that he was the India CFO for First Advantage, and for Apple wherein he was part of the team which led to Apple’s expansion in the India market. He has also held leadership roles at Procter & Gamble, and started his career at Ernst & Young India.
Deepak has over 25 years of experience managing multi-location operations and transactional revenues. He has successfully led business growth strategies working in different industries and is skilled in process engineering, distribution modelling, sales finance, tax compliance, and finance controlling across various regions and organizational structures.
Deepak is a Chartered Accountant with a Bachelor of Commerce degree from Calcutta University.
Andrew holds a Business Studies degree from Blackburn College of Technology, UK, and a professional qualification from the Institute of Personnel Management awarded by Salford Technical College, UK. His broad experience in the Human Resources function includes management of mergers and acquisitions; driving culture change; building a leadership and talent pipeline; and delivering a diversity agenda.
Andrew joined Syngene in December 2022 from management consultancy, Teneo, Hong Kong. Prior to joining Teneo he was CHRO for global retail group, DFS and held HR leadership roles at global biopharmaceutical company, AstraZeneca PLC. He started his career as an HR professional in the UK retail groups House of Fraser and Marks and Spencer PLC. Andrew is a member of the Executive Committee.
Alok holds an M. Tech in Chemical Technology (Food Technology) from Harcourt Butler Technological Institute. He comes with more than 25 years of experience spread across Manufacturing Operations, Quality Assurance, Sustainability/EHS, Production, and Supplier Technical Assurance across varied industries. Over the years, Alok has worked with leading corporates, including Dr. Reddy’s, Reckitt Benckiser, Pepsi Foods Ltd, Godrej Foods, and Beverages Ltd. In his recent assignment as Head of Global Quality Management at Dr. Reddy’s, he harmonized and integrated Quality management systems Globally and was also responsible for quality from all external suppliers and vendors. As Syngene’s CQO, Alok leads the Quality and Compliance function and will be in charge of initiatives to further strengthen our track record in quality and compliance
Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology and has pursued his Postdoctoral study in Natural product synthesis from the University of Texas. He has over two decades of experience in the areas of drug discovery for both small molecules and biologics and has been associated with organisations like Merck, Amplyx Pharmaceuticals Inc. and Sunesis. Prior to joining Syngene, Kenneth was the Head of R&D Strategic Global Operations at FORMA Therapeutics, where he was responsible for driving research effectiveness through optimisation of internal and external R&D research efforts, providing alliance management for key CRO relationships.
Alex has three decades of experience in developing, commercializing and life-cycle management of products in various life science industries. Holding positions in both the US and Europe, his experience includes senior roles with global P&L responsibility. Alex was Vice President Operations and Health COO at Johnson Matthey in Greater London in his last assignment. In addition, he has been instrumental in M&A, strategy development and new product introduction.
As a member of the Executive Committee, Alex plays a techno-commercial role, providing technical expertise to the API plant at Mangalore while building a sustainable client base for the business in collaboration with the commercial and business development teams. In addition, Alex is also responsible for biologics operations. Alex is based in Center Valley, Pennsylvania, USA.
Caroline Hempstead has a degree in French studies from Manchester University, UK. Her career spans more than 35 years in multinationals in sectors ranging from retail and financial services to oil & gas and pharmaceuticals. She joined Syngene in 2019 as Head of Corporate Affairs. Prior to joining Syngene, she held similar roles at AstraZeneca plc and LafargeHolcim (now Holcim), preceded by leadership roles in corporate communications at Royal Dutch Shell, Inchcape plc and the London Stock Exchange. As a member of the Executive Committee and the ESG Council, her responsibilities include embedding a deep focus on customer-centricity and stewardship of projects designed to expedite business performance.
Pramuch has completed the Global Program for Management Development from the Ross School of Business at the University of Michigan. He holds an MBA from the Birla Institute of Management Technology, New Delhi, and an English (Hons) degree from the University of Delhi. He also possesses certifications in digital marketing and a PGDM in public relations. Pramuch joined Syngene in August 2024 from the Mahindra Group, where he served as vice president and head of group communications. Prior to Mahindra, he has held positions at companies including Samsung India, Cisco Systems, IBM India, and Quark Inc. As a member of the Executive Committee and the ESG Council, his responsibilities encompass Corporate Communications, Public Affairs, and Environment, Social, and Governance (ESG) activities.
Jayashree has over 30 years of experience as a molecular pharmacologist and has led drug discovery programs in global organizations in the US like AstraZeneca, Merck, Ambrx and Theravance and Jubilant Biosys in India. Jayashree has more than 30 peer-reviewed publications and book chapters to her credit and two issued patents.
Jayashree joined Syngene in 2016 to lead the Discovery Biology function which has grown significantly under her leadership. In her role as Chief Scientific Officer, Jayashree plays a pivotal role in driving our scientific strategy and innovation in R&D, as well as strengthen academic and industry collaborations, ensuring that Syngene continues to lead with cutting-edge solutions for our clients.
Jayashree holds a Ph.D in Immunology from the All India Institute of Medical Sciences, New Delhi and post-doctoral research at the California Institute of Technology and the University of California at Irvine.
© 2023. Syngene International Limited